Notably, late Prox1 OE reduced GFP+ tumor nodules at the endpoint (219.5 versus 13.75 nodules) and significantly increased median survival from 17 to 36.5 days (Fig. 2j and Extended Data Fig. 3h,i), suggesting that PROX1 blocks tumor progression. The gene discussed is PROX1; the disease is neoplasm.